ES2315139A1 - Method for the determination of glucosaminoglyanes in urine and portable kit associated to this method. (Machine-translation by Google Translate, not legally binding) - Google Patents
Method for the determination of glucosaminoglyanes in urine and portable kit associated to this method. (Machine-translation by Google Translate, not legally binding) Download PDFInfo
- Publication number
- ES2315139A1 ES2315139A1 ES200603011A ES200603011A ES2315139A1 ES 2315139 A1 ES2315139 A1 ES 2315139A1 ES 200603011 A ES200603011 A ES 200603011A ES 200603011 A ES200603011 A ES 200603011A ES 2315139 A1 ES2315139 A1 ES 2315139A1
- Authority
- ES
- Spain
- Prior art keywords
- urine
- determination
- glycosaminoglycans
- color
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002700 urine Anatomy 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 12
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 238000012546 transfer Methods 0.000 claims abstract description 8
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical group C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 claims abstract description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims abstract description 6
- 239000003086 colorant Substances 0.000 claims abstract description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 238000012360 testing method Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 10
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 9
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000035977 Rare disease Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- NEUSVAOJNUQRTM-UHFFFAOYSA-N cetylpyridinium Chemical compound CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NEUSVAOJNUQRTM-UHFFFAOYSA-N 0.000 description 1
- 229960004830 cetylpyridinium Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000012994 industrial processing Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Método para la determinación de glucosaminoglicanos en orina y kit portátil asociado a este método.Method for determining urine glycosaminoglycans and portable kit associated with this method.
La presente invención es de aplicación para la detección rápida de excreción patológica de glucosaminoglicanos en orina, resultando especialmente válido para el diagnóstico de enfermedades raras tales como las enfermedades de Hunter y Hurler.The present invention is applicable to the rapid detection of pathological excretion of glycosaminoglycans in urine, proving especially valid for the diagnosis of rare diseases such as Hunter's diseases and Hurler.
El objeto de la invención consiste en obtener de un modo inmediato, con una buena sensibilidad y especificidad, y a un precio reducido, una ayuda en el diagnóstico de las enfermedades raras del grupo llamado mucopolisacaridosis.The object of the invention is to obtain from in an immediate way, with good sensitivity and specificity, and to a reduced price, an aid in the diagnosis of diseases rare of the group called mucopolysaccharidosis.
Dentro de las denominadas enfermedades raras (ER), el grupo llamado Mucopolisacaridosis (MPS) son un conjunto de trastornos hereditarios en que los diferentes tipos son clasificados en la literatura por los números romanos, y están causadas por deficiencia enzimática que impide la degradación de moléculas como son los glucosaminoglicanos (GAG) que se acumulan y se eliminan por orina.Within the so-called rare diseases (ER), the group called Mucopolysaccharidosis (MPS) are a set of inherited disorders in which the different types are classified in the literature by Roman numerals, and they are caused by enzymatic deficiency that prevents the degradation of molecules such as glycosaminoglycans (GAG) that accumulate and They are removed by urine.
La medida de la concentración de GAG en orina ha sido un procedimiento habitual de laboratorio para el diagnóstico de las MPS. Se han desarrollado diversos procedimientos hasta la actualidad: prueba de Berry, que utiliza azul de tolueno como reactivo y ácido acético como decolorante, prueba de cloruro de cetilpiridinio, basado en la interacción de los GAG con detergentes catiónicos y posterior turbidimetría, prueba de alcian blue basado en la formación de complejos, prueba del ácido urónico-carbazol previa precipitación del ácido urónico con detergentes catiónicos, prueba del 1-9 azul de dimetilmetileno basado en la determinación espectrométrica previa unión de los GAG a un cromógeno.The measurement of the concentration of GAG in urine has been a usual laboratory procedure for diagnosis of the MPS. Various procedures have been developed until the News: Berry test, which uses toluene blue as reagent and acetic acid as bleaching agent, chloride test cetylpyridinium, based on the interaction of GAGs with detergents cationic and subsequent turbidimetry, alcian blue based test in complex formation, acid test uronic-carbazole after acid precipitation uronic with cationic detergents, 1-9 test dimethylmethylene blue based on spectrometric determination previous union of the GAG to a chromogen.
Todos estos procedimientos analíticos no son especialmente dificultosos en los laboratorios especializados, pero claramente representan una dificultad para su empleo generalizado y esto es especialmente relevante si tenemos presente que la tardanza media en el diagnóstico es de 3 años.All these analytical procedures are not especially difficult in specialized laboratories, but clearly represent a difficulty for their widespread employment and This is especially relevant if we keep in mind that the The average delay in diagnosis is 3 years.
Hoy en día la sospecha diagnóstica no sólo se da a nivel pediátrico sino que se debe dar desde otras disciplinas, menos familiarizadas con las enfermedades raras, como es la oftalmología, cardiología, reumatología, etc, en la que el signo o síntoma de debut suele ser monosintomáticas (ejemplo túnel carpiano en adulto joven) y son difícilmente diferenciables con patología no relacionada con las MPS.Today the diagnostic suspicion not only occurs at the pediatric level but must be given from other disciplines, less familiar with rare diseases, such as ophthalmology, cardiology, rheumatology, etc., in which the sign or debut symptom is usually monosymptomatic (example carpal tunnel in young adults) and are hardly distinguishable with pathology not related to MPS.
Es fácil comprender la dificultad que entraña la logística actual del diagnóstico:It is easy to understand the difficulty involved in Current diagnostic logistics:
- --
- El médico no habituado a pensar en ER debe pensar en MPS.He Doctor not used to thinking about ER should think about MPS.
- --
- Debe enterarse o conocer cuales son los laboratorios especializados.Should find out or know what the laboratories are specialized.
- --
- El paciente debe acudir de nuevo a la consulta o laboratorio para toma de muestra biológica.He patient must go back to the office or laboratory to take of biological sample.
- --
- La muestra de orina debe enviarse en condiciones de conservación (refrigerada o congelada).The urine sample should be sent in storage condition (chilled or frozen).
- --
- Tiempo de demora de la respuesta.Weather of delayed response.
- --
- Información de los resultados.Information of the results.
- --
- Bajo índice de confirmación sobre la sospecha clínica.Low Confirmation index on clinical suspicion.
Todos estos hechos se complican mucho más en países en los que la infraestructura de laboratorios para la valoración de GAG es más deficiente.All these facts are much more complicated in countries in which the laboratory infrastructure for the GAG rating is more deficient.
Asimismo hay que tener presente el coste económico, y que las posibilidades de que el diagnóstico sea una MPS es muy baja 1/20.000 - 40.000 casos.You also have to keep in mind the cost economic, and that the chances that the diagnosis is a MPS is very low 1 / 20,000 - 40,000 cases.
El método y kit portátil para la determinación de glucosaminoglicanos en orina tiene como objetivo principal facilitar esta operación a un precio muy bajo con una buena sensibilidad y especificidad. Este kit permite realizar un test para el cribaje (screening) colimétrico y cualitativo de GAG en orina para la ayuda en el diagnóstico de las MPS, test que se puede realizar en la misma consulta del medico y de modo inmediato.The method and portable kit for determination of glucosaminoglycans in urine has as its main objective facilitate this operation at a very low price with a good sensitivity and specificity. This kit allows you to perform a test for the screening colimetric and qualitative of GAG in urine for help in the diagnosis of MPS, test that can be Perform in the same doctor's office and immediately.
Este kit se basa en una adaptación de pruebas de laboratorio para uso universal a muy bajo coste.This kit is based on a test adaptation of Laboratory for universal use at very low cost.
El kit comprende fundamentalmente:The kit basically includes:
- un dispositivo de transferencia de líquidos graduado, que puede consistir por ejemplo en una jeringuilla tipo insulina con escalas o en una pipeta, que se emplea para la toma de muestra de orina y permite obtener un volumen de 50 microlitros,- a liquid transfer device graduated, which may consist, for example, of a syringe type insulin with scales or in a pipette, which is used to take urine sample and allows to obtain a volume of 50 microliters,
- un envase transparente, que puede consistir en un vial o en una frasco con tapón que alberga un reactivo consistente en 1-9 azul de dimetilmetileno taponado con acetato a pH 4.1 en un volumen de 2 mililitros para combinar con 50 microlitros de muestra de orina para la obtención de una mezcla de un determinado color,- a transparent container, which may consist of a vial or bottle with a cap that houses a reagent consisting of 1-9 plugged dimethylmethylene blue with acetate at pH 4.1 in a volume of 2 milliliters to combine with 50 microliters of urine sample to obtain a mixture of a certain color,
- una escala de colores con la que se compara el color de la mezcla para evaluar la existencia de glucosaminoglicanos en la orina.- a color scale with which the color of the mixture to evaluate the existence of urine glycosaminoglycans
Se ha establecido una escala de color que determina tres niveles (test negativo, dudoso, positivo), con la adecuada sensibilidad y especificidad.A color scale has been established that determines three levels (negative, doubtful, positive test), with the adequate sensitivity and specificity.
De acuerdo con lo anterior el procedimiento para la determinación de glucosaminoglicanos en orina consiste en las fases de:In accordance with the above the procedure for the determination of glycosaminoglycans in urine consists of phases of:
- toma de una muestra de orina mediante el dispositivo de transferencia de líquidos graduado,- taking a urine sample using the graduated liquid transfer device,
- introducción de 50 microlitros de la muestra de orina en el envase transparente que contiene 2 ml de 1-9 azul de dimetilmetileno taponado con acetato a pH 4.1 para la obtención de una mezcla de color,- introduction of 50 microliters of the sample of urine in the transparent container containing 2 ml of 1-9 dimethylmethylene blue capped with acetate a pH 4.1 to obtain a color mixture,
- comparación del color de la mezcla con unos colores predefinidos de una escala de colores en el que la coincidencia con alguno de los colores de la escala constituye un indicativo positivo, negativo o dudoso de la existencia de glucosaminoglicanos en la muestra de orina.- comparison of the color of the mixture with some predefined colors of a color scale in which the coincidence with any of the colors of the scale constitutes a positive, negative or doubtful indicative of the existence of glycosaminoglycans in the urine sample.
El reactivo se ha taponado a un pH determinado para que pueda ser útil fuera del laboratorio, manteniéndose estable en condiciones ambientales por un período de al menos 12 meses, así como se han establecido las proporciones entre los volúmenes de reactivo y de la muestra de orina a estudiar, para que los virajes colimétricos sean claramente percibidos por la vista humana.The reagent has been capped at a certain pH so that it can be useful outside the laboratory, staying stable in environmental conditions for a period of at least 12 months, as well as the proportions between the volumes of reagent and urine sample to study, so that colimetric turns are clearly perceived by sight human
Una de las características de este test es que se puede realizar en la consulta del médico, sin necesidad de enviar muestras de orina a los laboratorios, esta facilidad permite que se realice un incremento de los diagnósticos.One of the characteristics of this test is that It can be done in the doctor's office, without the need for send urine samples to laboratories, this facility allows that an increase in diagnoses is made.
Otra característica es su estabilidad a temperatura ambiental, al estar el reactivo taponado, lo que facilita las condiciones de almacenamiento.Another feature is its stability at ambient temperature, when the reagent is plugged, which It facilitates storage conditions.
Se han obtenido unas relaciones volumétricas ideales del reactivo y de la muestra de orina con la finalidad de que la escala de valores presente una sensibilidad y especificidad aceptable para su empleo clínico.Volumetric relationships have been obtained ideals of the reagent and the urine sample for the purpose of that the scale of values presents a sensitivity and specificity acceptable for clinical use.
Las características de este test permite su procesamiento industrial a mayor o menor escala, en la que el kit contenga sus tres componentes (reactivo, dispositivo de transferencia de líquidos y escala colométrica), y como todo producto industrial con un manual de funcionamiento, interpretación de resultados y fecha de caducidad.The characteristics of this test allow its industrial processing on a larger or smaller scale, in which the kit contain its three components (reagent, device liquid transfer and colometric scale), and like everything industrial product with an operation manual, interpretation of results and expiration date.
El grupo de interés de este kit será el de profesionales de la salud que deseen realizar un cribaje de la sospecha de MPS con eliminación elevada de GAG, así como la industria farmacéutica que desarrolla tratamientos para estas enfermedades.The interest group of this kit will be the health professionals who wish to screen the suspicion of MPS with high GAG elimination, as well as pharmaceutical industry that develops treatments for these diseases.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
Para complementar la descripción que se está realizando y con objeto de ayudar a una mejor comprensión de las características de la invención, de acuerdo con un ejemplo preferente de realización práctica de la misma, se acompaña como parte integrante de dicha descripción, un juego de dibujos en donde con carácter ilustrativo y no limitativo, se ha representado lo siguiente:To complement the description that is being performing and in order to help a better understanding of the characteristics of the invention, according to an example preferred practical implementation of it, is accompanied as integral part of that description, a set of drawings where with an illustrative and non-limiting nature, what has been represented next:
Figura 1.- Muestra una realización en la que se han representado los componentes del kit portátil para la determinación de glucosaminoglicanos.Figure 1.- Shows an embodiment in which have represented the components of the portable kit for the Determination of glycosaminoglycans.
Figura 2.- Muestra otra realización en la que se han representado los componentes del kit portátil para la determinación de glucosaminoglicanos.Figure 2.- Shows another embodiment in which have represented the components of the portable kit for the Determination of glycosaminoglycans.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
Con referencia a las figuras se describen dos modos de realización preferente del kit portátil para la determinación de glucosaminoglicanos en orina que constituye el objeto de esta invención.With reference to the figures two are described preferred embodiments of the portable kit for determination of glycosaminoglycans in urine constituting the object of this invention.
En una primera realización representada en la figura 1 se observa el kit formado por una jeringuilla (1), un vial (2) y una escala de colores (3) y en una segunda realización se ha representado una pipeta (4), un frasco dotado de un tapón (5) y una escala de colores (3).In a first embodiment represented in the Figure 1 shows the kit formed by a syringe (1), a vial (2) and a color scale (3) and in a second embodiment it has been represented a pipette (4), a bottle provided with a cap (5) and a color scale (3).
En ambos casos la muestra de orina es transferida, bien desde la jeringuilla (1) o desde la pipeta (4) hacia un vial (2) o hacia un frasco dotado de tapón (5) respectivamente, en el que se alberga el reactivo 1-9 azul de dimetilmetileno taponado con acetato a pH 4.1 con el que reacciona la orina para obtener una mezcla de un color determinado que se compara con la escala de colores (3).In both cases the urine sample is transferred, either from the syringe (1) or from the pipette (4) to a vial (2) or to a bottle with a cap (5) respectively, in which the reagent is housed 1-9 dimethylmethylene blue capped with acetate a pH 4.1 with which the urine reacts to obtain a mixture of a determined color that compares with the color scale (3).
En la escala de colores (3) se han representado tres cuadros (3.1, 3.2, 3.3), un primer cuadro (3.1) correspondiente a un color indicativo de la no existencia de glucosaminoglicanos en la orina, un segundo cuadro (3.2) indicativo de tratarse de un caso dudoso y un tercer cuadro (3.3) indicativo de la existencia de glucosaminoglicanos en la orina.In the color scale (3) they have been represented three frames (3.1, 3.2, 3.3), a first frame (3.1) corresponding to a color indicative of the non-existence of urine glycosaminoglycans, a second indicative box (3.2) if it is a doubtful case and a third indicative table (3.3) of the existence of glycosaminoglycans in the urine.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200603011A ES2315139B1 (en) | 2006-11-24 | 2006-11-24 | METHOD FOR THE DETERMINATION OF GLUCOSAMINOGLYCANS IN URINE AND PORTABLE KIT ASSOCIATED WITH THIS METHOD. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200603011A ES2315139B1 (en) | 2006-11-24 | 2006-11-24 | METHOD FOR THE DETERMINATION OF GLUCOSAMINOGLYCANS IN URINE AND PORTABLE KIT ASSOCIATED WITH THIS METHOD. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2315139A1 true ES2315139A1 (en) | 2009-03-16 |
| ES2315139B1 ES2315139B1 (en) | 2009-12-30 |
Family
ID=40410135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200603011A Expired - Fee Related ES2315139B1 (en) | 2006-11-24 | 2006-11-24 | METHOD FOR THE DETERMINATION OF GLUCOSAMINOGLYCANS IN URINE AND PORTABLE KIT ASSOCIATED WITH THIS METHOD. |
Country Status (1)
| Country | Link |
|---|---|
| ES (1) | ES2315139B1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5310646A (en) * | 1988-05-13 | 1994-05-10 | Regents Of The University Of Minnesota | Method for the detection of mucopolysaccharide storage diseases |
-
2006
- 2006-11-24 ES ES200603011A patent/ES2315139B1/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5310646A (en) * | 1988-05-13 | 1994-05-10 | Regents Of The University Of Minnesota | Method for the detection of mucopolysaccharide storage diseases |
Non-Patent Citations (5)
Also Published As
| Publication number | Publication date |
|---|---|
| ES2315139B1 (en) | 2009-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guder | History of the preanalytical phase: a personal view | |
| Sánchez et al. | Semen analysis: update on clinical value, current needs and future perspectives | |
| Howanitz et al. | Practices for identifying and rejecting hemolyzed specimens are highly variable in clinical laboratories | |
| ES2727086T3 (en) | Container for the determination of analytes and / or physicochemical parameters, as well as for the determination of urine sediment in the urine, and complete urine analysis procedure using this container | |
| JP6678640B2 (en) | Biological sample storage systems and labels | |
| Gerday et al. | Urinary ferritin; a potential noninvasive way to screen NICU patients for iron deficiency | |
| Sudha et al. | Quantification of sweat urea in diabetes using electro-optical technique | |
| ES2315139B1 (en) | METHOD FOR THE DETERMINATION OF GLUCOSAMINOGLYCANS IN URINE AND PORTABLE KIT ASSOCIATED WITH THIS METHOD. | |
| Miyazaki et al. | Screening for proteinuria in cats using a conventional dipstick test after removal of cauxin from urine with a Lens culinaris agglutinin lectin tip | |
| Manus et al. | The evaluation of delirium post‐stroke | |
| Ouvrier et al. | SYSTEMS: School-years screening test for the evaluation of mental status | |
| Conners | Conners comprehensive behavior rating scales (Conners CBRS) | |
| Serjeant et al. | Newborn screening for sickle cell disease in Jamaica: logistics and experience with umbilical cord samples | |
| Kowalewski et al. | Collection, processing, and storage consideration for urinary biomarker research | |
| Tighe | Laboratory-based quality assurance programme for near-patient urine dipstick testing, 1990-1997: development, management and results | |
| Tworek et al. | The rate of manual microscopic examination of urine sediment: a College of American Pathologists Q-Probes study of 11 243 urinalysis tests from 88 institutions | |
| Çelik et al. | Assessment of hair zinc in the school children in Kayseri, Turkey | |
| Auray-Blais et al. | UPLC–MS/MS analysis of keratan sulfate from urine samples collected on filter paper for monitoring & follow-up of Morquio A patients | |
| US20070196927A1 (en) | Method For Qualitative And/Or Quantitative Detection Of Polyethylene Glycols In Biological Fluids | |
| Hodgson et al. | Development and validation of a multivariate predictive model to estimate serum ionized calcium concentration from serum biochemical profile results in cats | |
| Tucker et al. | Colorimetric determination of pH | |
| Nazarenko | Optical sensors for manual and automatic titration in undergraduate laboratory | |
| He et al. | Evaluatiing the Effects of HIV Self-testing used Professional Rapid Test Kits among MSM in Some Areas of China. | |
| Dowling et al. | Analysis of the saliva proteome using 2D-DIGE | |
| Alonso et al. | Determination of the pKa value of phenolphthalein by means of absorbance measurements |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20090316 Kind code of ref document: A1 |
|
| FG2A | Definitive protection |
Ref document number: 2315139B1 Country of ref document: ES |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20211117 |